Previous close | 6,300.80 |
Open | 6,324.00 |
Bid | 6,266.95 x 0 |
Ask | 6,251.45 x 0 |
Day's range | 6,200.05 - 6,348.00 |
52-week range | 4,383.40 - 6,505.50 |
Volume | |
Avg. volume | 13,631 |
Market cap | 1.042T |
Beta (5Y monthly) | 0.34 |
PE ratio (TTM) | 19.99 |
EPS (TTM) | 313.15 |
Earnings date | 07 May 2024 |
Forward dividend & yield | 40.00 (0.63%) |
Ex-dividend date | 11 Jul 2023 |
1y target est | 2,581.68 |
HYDERABAD, India, May 07, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024.
HYDERABAD, India, May 03, 2024--Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S. market.
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c